Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Talpaz

Showing results (321-330 of 350) with videos related to

Pageof 35
Sort By:
Eye (London, England)|January 24, 2004
Periorbital oedema and epiphora as ocular side effects of imatinib mesylate (Gleevec)B Esmaeli, R Diba, M A Ahmadi, et al.
Annals of Internal Medicine|November 1, 1986
Rearrangement in the breakpoint cluster region and the clinical course in Philadelphia-negative chronic myelogenous leukemiaR Kurzrock, M B Blick, M Talpaz, et al.
Blood|September 15, 1995
Hypermetaphase fluorescence in situ hybridization for quantitative monitoring of Philadelphia chromosome-positive cells in patients with chronic myelogenous leukemia during treatmentD C Seong, H M Kantarjian, J Y Ro, et al.
Cancer|December 14, 1999
Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patientsS Sacchi, H M Kantarjian, S O'Brien, et al.
Blood|June 11, 1999
Sequential homoharringtonine and interferon-alpha in the treatment of early chronic phase chronic myelogenous leukemiaS O'Brien, H Kantarjian, C Koller, et al.
Blood|May 1, 1990
Treatment of poor-prognosis, newly diagnosed acute myeloid leukemia with ara-C and recombinant human granulocyte-macrophage colony-stimulating factorE H Estey, D Dixon, H M Kantarjian, et al.
Leukemia & Lymphoma|December 28, 1999
Unexpected high incidence of severe toxicities associated with alpha interferon, low-dose cytosine arabinoside and all-trans retinoic acid in patients with chronic myelogenous leukemiaS Sacchi, H M Kantarjian, E J Freireich, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1991
Alteration in interactions between tumor-infiltrating lymphocytes and tumor cells in human melanomas after chemotherapy or immunotherapyK Itoh, K Hayakawa, M A Salmeron, et al.
Leukemia|January 30, 2010
ON012380, a putative BCR-ABL kinase inhibitor with a unique mechanism of action in imatinib-resistant cellsJ Wu, F Meng, Y Ying, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 14, 2000
Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemiaH M Kantarjian, M Talpaz, T L Smith, et al.
Pageof 35

Showing results (321-330 of 350) with videos related to

Sort By:
Pageof 35
Eye (London, England)|January 24, 2004
Periorbital oedema and epiphora as ocular side effects of imatinib mesylate (Gleevec)B Esmaeli, R Diba, M A Ahmadi, et al.
Annals of Internal Medicine|November 1, 1986
Rearrangement in the breakpoint cluster region and the clinical course in Philadelphia-negative chronic myelogenous leukemiaR Kurzrock, M B Blick, M Talpaz, et al.
Blood|September 15, 1995
Hypermetaphase fluorescence in situ hybridization for quantitative monitoring of Philadelphia chromosome-positive cells in patients with chronic myelogenous leukemia during treatmentD C Seong, H M Kantarjian, J Y Ro, et al.
Cancer|December 14, 1999
Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patientsS Sacchi, H M Kantarjian, S O'Brien, et al.
Blood|June 11, 1999
Sequential homoharringtonine and interferon-alpha in the treatment of early chronic phase chronic myelogenous leukemiaS O'Brien, H Kantarjian, C Koller, et al.
Blood|May 1, 1990
Treatment of poor-prognosis, newly diagnosed acute myeloid leukemia with ara-C and recombinant human granulocyte-macrophage colony-stimulating factorE H Estey, D Dixon, H M Kantarjian, et al.
Leukemia & Lymphoma|December 28, 1999
Unexpected high incidence of severe toxicities associated with alpha interferon, low-dose cytosine arabinoside and all-trans retinoic acid in patients with chronic myelogenous leukemiaS Sacchi, H M Kantarjian, E J Freireich, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1991
Alteration in interactions between tumor-infiltrating lymphocytes and tumor cells in human melanomas after chemotherapy or immunotherapyK Itoh, K Hayakawa, M A Salmeron, et al.
Leukemia|January 30, 2010
ON012380, a putative BCR-ABL kinase inhibitor with a unique mechanism of action in imatinib-resistant cellsJ Wu, F Meng, Y Ying, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 14, 2000
Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemiaH M Kantarjian, M Talpaz, T L Smith, et al.
Pageof 35